Some Science of Pro 140 (PA14) (Leronlimab) ccr5 c
Post# of 148321
(Total Views: 9918)
Posted On: 11/29/2019 9:12:10 PM
Some Science of Pro 140 (PA14) (Leronlimab) ccr5 cydy cytodyn tnbc nash hiv
Differential inhibition of human immunodeficiency virus type 1 fusion, gp120 binding, and CC-chemokine activity by monoclonal antibodies to CCR5
William C. Olson, Gwénaël E. E. Rabut, Kirsten A. Nagashima, Diep N. H. Tran, Deborah J. Anselma, Simon P. Monard, Jeremy P. Segal, Daniah A. D. Thompson, Francis Kajumo, Yong Guo, John P. Moore, Paul J. Maddon, Tatjana Dragic
Journal of Virology May 1999, 73 (5) 4145-4155;
https://jvi.asm.org/content/73/5/4145.short
Potent, Broad-Spectrum Inhibition of Human Immunodeficiency Virus Type 1 by the CCR5 Monoclonal Antibody PRO 140
Alexandra Trkola, Thomas J. Ketas, Kirsten A. Nagashima, Lu Zhao, Tonie Cilliers, Lynn Morris, John P. Moore, Paul J. Maddon, William C. Olson
Journal of Virology Jan 2001, 75 (2) 579-588
https://jvi.asm.org/content/75/2/579.short
HIV-1 escape from a small molecule, CCR5-specific entry inhibitor does not involve CXCR4 use
Alexandra Trkola, Shawn E. Kuhmann, Julie M. Strizki, Elizabeth Maxwell, Tom Ketas, Tom Morgan, Pavel Pugach, Serena Xu, Lisa Wojcik, Jayaram Tagat, Anandan Palani, Sherry Shapiro, John W. Clader, Stuart McCombie, Gregory R. Reyes, Bahige M. Baroudy, and John P. Moore
PNAS January 8, 2002 99 (1) 395-400
https://www.pnas.org/content/99/1/395.short
HIV entry inhibitors: mechanisms of action and resistance pathways
Verónica Briz, Eva Poveda, Vincent Soriano
Journal of Antimicrobial Chemotherapy, Volume 57, Issue 4, April 2006, Pages 619–627,
https://academic.oup.com/jac/article/57/4/619/669426
Susceptibility of pediatric HIV-1 isolates to recombinant CD4-IgG2 (PRO 542) and humanized mAb to the chemokine receptor CCR5 (PRO 140)
Shearer, William T; DeVille, Jaime G; Samson, Pearl M; Moye, John H; Fletcher, Courtney V
Journal of Allergy and Clinical Immunology; St. Louis Vol. 118, Iss. 2, (Aug 2006): 518-521
https://search.proquest.com/openview/35e40dec...806d0113/1
An anti-CCR5 monoclonal antibody and small molecule CCR5 antagonists synergize by inhibiting different stages of human immunodeficiency virus type 1 entry
Diana Safariana Xavier Carneca,Fotini Tsamisa, Francis Kajumoab, Tatjana Dragica
Virology
Volume 352, Issue 2, 1 September 2006, Pages 477-484
https://www.sciencedirect.com/science/article...2206003369
Potent Antiviral Synergy between Monoclonal Antibody and Small-Molecule CCR5 Inhibitors of Human Immunodeficiency Virus Type 1
Jose D. Murga, Michael Franti, Daniel C. Pevear, Paul J. Maddon, William C. Olson
Antimicrobial Agents and Chemotherapy Sep 2006, 50 (10) 3289-3296;
https://aac.asm.org/content/50/10/3289.short
HIV-1 clones resistant to a small molecule CCR5 inhibitor use the inhibitor-bound form of CCR5 for entry
Pavel Pugach, Andre Marozsan, Thomas Ketas, Elissa Landes, John Moore, Shawn Kuhmann
Virology Volume 361, Issue 1, 25 April 2007, Pages 212-228
https://www.sciencedirect.com/science/article...2206008245
Antiviral Activity of Single-Dose PRO 140, a CCR5 Monoclonal Antibody, in HIV-Infected Adults
Jeffrey M. Jacobson, Michael S. Saag, Melanie A. Thompson, Margaret A. Fischl, Ralph Liporace, Richard C. Reichman, Robert R. Redfield, Carl J. Fichtenbaum, Barry S. Zingman, Mahesh C. Patel, Jose D. Murga, Suzanne M. Pemrick, Paul D'Ambrosio, Marti Michael, Hans Kroger, Hieu Ly, Yakov Rotshteyn, Robert Buice, Stephen A. Morris, Joseph J. Stavola, Paul J. Maddon, Alton B. Kremer, William C. Olson
The Journal of Infectious Diseases, Volume 198, Issue 9, 1 November 2008, Pages 1345–1352
https://academic.oup.com/jid/article/198/9/1345/834086
Single-Dose PRO 140 Has Lasting Effects
Tim Horn, 21 Sept 2007. POZ.com
https://www.poz.com/article/Single-Dose-PRO-1...13079-7759
ICAAC: Phase 1 study provides `proof of concept` for PRO 140, a monoclonal CCR5 antibody
Derek Thaczuk, 21 September 2007
https://www.aidsmap.com/news/sep-2007/icaac-p...5-antibody
New approaches in the treatment of HIV/AIDS – focus on maraviroc and other CCR5 antagonists
Hans P Schlecht, Sarah Schellhorn, Bruce J Dezube, and Jeffrey M Jacobson
Ther Clin Risk Manag. 2008 Apr; 4(2): 473–485.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2504054/
CCR5 Monoclonal Antibodies for HIV-1 Therapy
William C. Olson and Jeffrey M. Jacobson
Curr Opin HIV AIDS. 2009 Mar; 4(2): 104–111.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2760828/
Phase 2a Study of the CCR5 Monoclonal Antibody PRO 140 Administered Intravenously to HIV-Infected Adults
Jeffrey M. Jacobson, Jacob P. Lalezari, Melanie A. Thompson, Carl J. Fichtenbaum, Michael S. Saag, Barry S. Zingman, Paul D'Ambrosio, Nancy Stambler, Yakov Rotshteyn, Andre J. Marozsan, Paul J. Maddon, Stephen A. Morris, William C. Olson
Antimicrobial Agents and Chemotherapy Sep 2010, 54 (10) 4137-4142
https://aac.asm.org/content/54/10/4137.short
Anti-HIV-1 Activity of Weekly or Biweekly Treatment with Subcutaneous PRO 140, a CCR5 Monoclonal Antibody
Jeffrey M. Jacobson, Melanie A. Thompson, Jacob P. Lalezari, Michael S. Saag, Paul Zingman, Barry S. D'Ambrosio, Nancy Stambler, Yakov Rotshteyn, Andre J. Marozsan, Paul J. Maddon, Stephen A. Morris, William C. Olson
The Journal of Infectious Diseases, Volume 201, Issue 10, 15 May 2010, Pages 1481–1487
https://academic.oup.com/jid/article/201/10/1481/992206
PRO 140 - A Novel CCR5 Co-Receptor Inhibitor
Khatib, Nadia; Das, Satyajit
Recent Patents on Anti-Infective Drug Discovery, Volume 5, Number 1, 2010, pp. 18-22(5)
https://www.ingentaconnect.com/content/ben/pr...1/art00003
The Monoclonal CCR5 Antibody PRO-140: The Promise of Once-Weekly HIV Therapy
Jacobson JM, Thompson MA, Lalezari JP, et al.: Anti–HIV-1 activity of weekly or biweekly treatment with subcutaneous PRO 140, a CCR5 monoclonal antibody.
Journal Infect Dis 2010, 201:1481–1487.
https://link.springer.com/article/10.1007/s11904-010-0068-y
Combinatorial Approaches to the Prevention and Treatmentof HIV-1 Infection
Pirrone V, Thakkar N, Jacobson JM, Wigdahl B, Krebs FC.
Antimicrob Agents Chemother. 2011 May;55(5):1831-42
https://www.ncbi.nlm.nih.gov/pubmed/21343462
Synergistic Inhibition of R5 HIV-1 by Maraviroc and CCR5 Antibody HGS004 in Primary Cells: Implications for Treatment and Prevention
OLGA LATINOVIC,a NHUT LE,a MARVIN REITZ,a RANAJIT PAL,b ANTHONY DEVICO,a JAMES S. FOULKE,a ROBERT R. REDFIELD,a and ALONSO HEREDIAa
AIDS. 2011 Jun 1; 25(9): 1232–1235.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3748726/
Humanized PA14 (a monoclonal CCR5 antibody) for treatment of people with HIV infection.
Li L, Tian JH, Yang K, Zhang P, Jia WQ.
Cochrane Database Syst Rev. 2014 Jul 26
7):CD008439.
https://www.ncbi.nlm.nih.gov/pubmed/25063928
PRO 140 Monoclonal Antibody to CCR5 Prevents Acute Xenogeneic Graft-versus-Host Disease in NOD-scid IL-2Rynull Mice.
Bioliogy Blood Marrow Transplant. 2018 Feb;24(2):260-266
Burger DR, Parker Y, Guinta K, Lindner D.
https://www.ncbi.nlm.nih.gov/pubmed/29128556
PRO 140, a monoclonal antibody targeting CCR5, as a long-acting, single-agent maintenance therapy for HIV-1 infection
Dhody K, Pourhassan N, Kazempour K, Green D, Badri S, Mekonnen H, Burger D, Maddon PJ
HIV Clin Trials. 2018 Jun;19(3):85-93
https://www.ncbi.nlm.nih.gov/pubmed/29676212
The return of PRO 140, a CCR5-directed mAb
Thompson MA
Current Opinion HIV AIDS. 2018 Jul;13(4):346-353
https://www.ncbi.nlm.nih.gov/pubmed/29708899
PRO 140 Single-Agent Maintenance Therapy for HIV-1 Infection: A 2-Year Update
Jay Lalezari, Kush Dhody, Ula Kowalczyk, Kazem Kazempour, Nader Pourhassan and Paul J. Maddon
ASM 2018 COMBO Poster
https://content.equisolve.net/_f8eaae214fb1b6...b5fc98.pdf
Primary Efficacy Results of PRO 140 SC in a Pivotal Phase 2b/3 Study in Heavily Treatment-Experienced HIV-1 Patients
ASM 2018 COMBO Poster
Kush Dhody, Kazem Kazempour, Nader Pourhassan and Paul J. Maddon
https://content.equisolve.net/_f8eaae214fb1b6...c8e1bd.pdf
PRO 140 (leronlimab) SC: Long-Acting Single-Agent Maintenance Therapy
CROI 2019 MONO Poster
Kush Dhody, Kazem Kazempour, Nader Pourhassan and Paul J. Maddon
http://www.croiconference.org/sites/default/f...y_0486.pdf
Leronlimab, a humanized monoclonal antibody to CCR5, blocks breast cancer metastasis and enhances cell death induced by DNA damaging chemotherapy
Xuanmao Jiao, Min Wang, Zhiping Li, Richard G. Pestell
AACR 2019
https://s3.amazonaws.com/content.stockpr.com/...%20(1).pdf
Final Results of the Pivotal Study of PRO 140 SC in Heavily Treatment-Experienced HIV Patients
Kush Dhody, Kazem Kazempour, Nader Pourhassan, and Paul J. Maddon
ASM 2019 COMBO Poster
https://content.equisolve.net/_f8eaae214fb1b6..._Final.pdf
Recent Advances Targeting CCR5 for Cancer and Its Role in Immuno-Oncology
Xuanmao Jiao, Omar Nawab, Tejal Patel, Andrew V. Kossenkov, Niels Halama, Dirk Jaeger and Richard G. Pestell
Cancer Research Journal, October 2019 Volume 79, Issue 19
https://cancerres.aacrjournals.org/content/79/19/4801.short
Cytokine CCL5 and receptor CCR5 axis in glioblastoma multiforme
Miha Koprivnikar Kranjc, Metka Novak, Richard G. Pestell, Prof. Tamara T. Lah
The Journal of Association of Radiology and Oncology, Vol 53, Iss 4
https://www.degruyter.com/view/j/raon.2019.53...9-0057.xml
Differential inhibition of human immunodeficiency virus type 1 fusion, gp120 binding, and CC-chemokine activity by monoclonal antibodies to CCR5
William C. Olson, Gwénaël E. E. Rabut, Kirsten A. Nagashima, Diep N. H. Tran, Deborah J. Anselma, Simon P. Monard, Jeremy P. Segal, Daniah A. D. Thompson, Francis Kajumo, Yong Guo, John P. Moore, Paul J. Maddon, Tatjana Dragic
Journal of Virology May 1999, 73 (5) 4145-4155;
https://jvi.asm.org/content/73/5/4145.short
Potent, Broad-Spectrum Inhibition of Human Immunodeficiency Virus Type 1 by the CCR5 Monoclonal Antibody PRO 140
Alexandra Trkola, Thomas J. Ketas, Kirsten A. Nagashima, Lu Zhao, Tonie Cilliers, Lynn Morris, John P. Moore, Paul J. Maddon, William C. Olson
Journal of Virology Jan 2001, 75 (2) 579-588
https://jvi.asm.org/content/75/2/579.short
HIV-1 escape from a small molecule, CCR5-specific entry inhibitor does not involve CXCR4 use
Alexandra Trkola, Shawn E. Kuhmann, Julie M. Strizki, Elizabeth Maxwell, Tom Ketas, Tom Morgan, Pavel Pugach, Serena Xu, Lisa Wojcik, Jayaram Tagat, Anandan Palani, Sherry Shapiro, John W. Clader, Stuart McCombie, Gregory R. Reyes, Bahige M. Baroudy, and John P. Moore
PNAS January 8, 2002 99 (1) 395-400
https://www.pnas.org/content/99/1/395.short
HIV entry inhibitors: mechanisms of action and resistance pathways
Verónica Briz, Eva Poveda, Vincent Soriano
Journal of Antimicrobial Chemotherapy, Volume 57, Issue 4, April 2006, Pages 619–627,
https://academic.oup.com/jac/article/57/4/619/669426
Susceptibility of pediatric HIV-1 isolates to recombinant CD4-IgG2 (PRO 542) and humanized mAb to the chemokine receptor CCR5 (PRO 140)
Shearer, William T; DeVille, Jaime G; Samson, Pearl M; Moye, John H; Fletcher, Courtney V
Journal of Allergy and Clinical Immunology; St. Louis Vol. 118, Iss. 2, (Aug 2006): 518-521
https://search.proquest.com/openview/35e40dec...806d0113/1
An anti-CCR5 monoclonal antibody and small molecule CCR5 antagonists synergize by inhibiting different stages of human immunodeficiency virus type 1 entry
Diana Safariana Xavier Carneca,Fotini Tsamisa, Francis Kajumoab, Tatjana Dragica
Virology
Volume 352, Issue 2, 1 September 2006, Pages 477-484
https://www.sciencedirect.com/science/article...2206003369
Potent Antiviral Synergy between Monoclonal Antibody and Small-Molecule CCR5 Inhibitors of Human Immunodeficiency Virus Type 1
Jose D. Murga, Michael Franti, Daniel C. Pevear, Paul J. Maddon, William C. Olson
Antimicrobial Agents and Chemotherapy Sep 2006, 50 (10) 3289-3296;
https://aac.asm.org/content/50/10/3289.short
HIV-1 clones resistant to a small molecule CCR5 inhibitor use the inhibitor-bound form of CCR5 for entry
Pavel Pugach, Andre Marozsan, Thomas Ketas, Elissa Landes, John Moore, Shawn Kuhmann
Virology Volume 361, Issue 1, 25 April 2007, Pages 212-228
https://www.sciencedirect.com/science/article...2206008245
Antiviral Activity of Single-Dose PRO 140, a CCR5 Monoclonal Antibody, in HIV-Infected Adults
Jeffrey M. Jacobson, Michael S. Saag, Melanie A. Thompson, Margaret A. Fischl, Ralph Liporace, Richard C. Reichman, Robert R. Redfield, Carl J. Fichtenbaum, Barry S. Zingman, Mahesh C. Patel, Jose D. Murga, Suzanne M. Pemrick, Paul D'Ambrosio, Marti Michael, Hans Kroger, Hieu Ly, Yakov Rotshteyn, Robert Buice, Stephen A. Morris, Joseph J. Stavola, Paul J. Maddon, Alton B. Kremer, William C. Olson
The Journal of Infectious Diseases, Volume 198, Issue 9, 1 November 2008, Pages 1345–1352
https://academic.oup.com/jid/article/198/9/1345/834086
Single-Dose PRO 140 Has Lasting Effects
Tim Horn, 21 Sept 2007. POZ.com
https://www.poz.com/article/Single-Dose-PRO-1...13079-7759
ICAAC: Phase 1 study provides `proof of concept` for PRO 140, a monoclonal CCR5 antibody
Derek Thaczuk, 21 September 2007
https://www.aidsmap.com/news/sep-2007/icaac-p...5-antibody
New approaches in the treatment of HIV/AIDS – focus on maraviroc and other CCR5 antagonists
Hans P Schlecht, Sarah Schellhorn, Bruce J Dezube, and Jeffrey M Jacobson
Ther Clin Risk Manag. 2008 Apr; 4(2): 473–485.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2504054/
CCR5 Monoclonal Antibodies for HIV-1 Therapy
William C. Olson and Jeffrey M. Jacobson
Curr Opin HIV AIDS. 2009 Mar; 4(2): 104–111.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2760828/
Phase 2a Study of the CCR5 Monoclonal Antibody PRO 140 Administered Intravenously to HIV-Infected Adults
Jeffrey M. Jacobson, Jacob P. Lalezari, Melanie A. Thompson, Carl J. Fichtenbaum, Michael S. Saag, Barry S. Zingman, Paul D'Ambrosio, Nancy Stambler, Yakov Rotshteyn, Andre J. Marozsan, Paul J. Maddon, Stephen A. Morris, William C. Olson
Antimicrobial Agents and Chemotherapy Sep 2010, 54 (10) 4137-4142
https://aac.asm.org/content/54/10/4137.short
Anti-HIV-1 Activity of Weekly or Biweekly Treatment with Subcutaneous PRO 140, a CCR5 Monoclonal Antibody
Jeffrey M. Jacobson, Melanie A. Thompson, Jacob P. Lalezari, Michael S. Saag, Paul Zingman, Barry S. D'Ambrosio, Nancy Stambler, Yakov Rotshteyn, Andre J. Marozsan, Paul J. Maddon, Stephen A. Morris, William C. Olson
The Journal of Infectious Diseases, Volume 201, Issue 10, 15 May 2010, Pages 1481–1487
https://academic.oup.com/jid/article/201/10/1481/992206
PRO 140 - A Novel CCR5 Co-Receptor Inhibitor
Khatib, Nadia; Das, Satyajit
Recent Patents on Anti-Infective Drug Discovery, Volume 5, Number 1, 2010, pp. 18-22(5)
https://www.ingentaconnect.com/content/ben/pr...1/art00003
The Monoclonal CCR5 Antibody PRO-140: The Promise of Once-Weekly HIV Therapy
Jacobson JM, Thompson MA, Lalezari JP, et al.: Anti–HIV-1 activity of weekly or biweekly treatment with subcutaneous PRO 140, a CCR5 monoclonal antibody.
Journal Infect Dis 2010, 201:1481–1487.
https://link.springer.com/article/10.1007/s11904-010-0068-y
Combinatorial Approaches to the Prevention and Treatmentof HIV-1 Infection
Pirrone V, Thakkar N, Jacobson JM, Wigdahl B, Krebs FC.
Antimicrob Agents Chemother. 2011 May;55(5):1831-42
https://www.ncbi.nlm.nih.gov/pubmed/21343462
Synergistic Inhibition of R5 HIV-1 by Maraviroc and CCR5 Antibody HGS004 in Primary Cells: Implications for Treatment and Prevention
OLGA LATINOVIC,a NHUT LE,a MARVIN REITZ,a RANAJIT PAL,b ANTHONY DEVICO,a JAMES S. FOULKE,a ROBERT R. REDFIELD,a and ALONSO HEREDIAa
AIDS. 2011 Jun 1; 25(9): 1232–1235.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3748726/
Humanized PA14 (a monoclonal CCR5 antibody) for treatment of people with HIV infection.
Li L, Tian JH, Yang K, Zhang P, Jia WQ.
Cochrane Database Syst Rev. 2014 Jul 26
7):CD008439. https://www.ncbi.nlm.nih.gov/pubmed/25063928
PRO 140 Monoclonal Antibody to CCR5 Prevents Acute Xenogeneic Graft-versus-Host Disease in NOD-scid IL-2Rynull Mice.
Bioliogy Blood Marrow Transplant. 2018 Feb;24(2):260-266
Burger DR, Parker Y, Guinta K, Lindner D.
https://www.ncbi.nlm.nih.gov/pubmed/29128556
PRO 140, a monoclonal antibody targeting CCR5, as a long-acting, single-agent maintenance therapy for HIV-1 infection
Dhody K, Pourhassan N, Kazempour K, Green D, Badri S, Mekonnen H, Burger D, Maddon PJ
HIV Clin Trials. 2018 Jun;19(3):85-93
https://www.ncbi.nlm.nih.gov/pubmed/29676212
The return of PRO 140, a CCR5-directed mAb
Thompson MA
Current Opinion HIV AIDS. 2018 Jul;13(4):346-353
https://www.ncbi.nlm.nih.gov/pubmed/29708899
PRO 140 Single-Agent Maintenance Therapy for HIV-1 Infection: A 2-Year Update
Jay Lalezari, Kush Dhody, Ula Kowalczyk, Kazem Kazempour, Nader Pourhassan and Paul J. Maddon
ASM 2018 COMBO Poster
https://content.equisolve.net/_f8eaae214fb1b6...b5fc98.pdf
Primary Efficacy Results of PRO 140 SC in a Pivotal Phase 2b/3 Study in Heavily Treatment-Experienced HIV-1 Patients
ASM 2018 COMBO Poster
Kush Dhody, Kazem Kazempour, Nader Pourhassan and Paul J. Maddon
https://content.equisolve.net/_f8eaae214fb1b6...c8e1bd.pdf
PRO 140 (leronlimab) SC: Long-Acting Single-Agent Maintenance Therapy
CROI 2019 MONO Poster
Kush Dhody, Kazem Kazempour, Nader Pourhassan and Paul J. Maddon
http://www.croiconference.org/sites/default/f...y_0486.pdf
Leronlimab, a humanized monoclonal antibody to CCR5, blocks breast cancer metastasis and enhances cell death induced by DNA damaging chemotherapy
Xuanmao Jiao, Min Wang, Zhiping Li, Richard G. Pestell
AACR 2019
https://s3.amazonaws.com/content.stockpr.com/...%20(1).pdf
Final Results of the Pivotal Study of PRO 140 SC in Heavily Treatment-Experienced HIV Patients
Kush Dhody, Kazem Kazempour, Nader Pourhassan, and Paul J. Maddon
ASM 2019 COMBO Poster
https://content.equisolve.net/_f8eaae214fb1b6..._Final.pdf
Recent Advances Targeting CCR5 for Cancer and Its Role in Immuno-Oncology
Xuanmao Jiao, Omar Nawab, Tejal Patel, Andrew V. Kossenkov, Niels Halama, Dirk Jaeger and Richard G. Pestell
Cancer Research Journal, October 2019 Volume 79, Issue 19
https://cancerres.aacrjournals.org/content/79/19/4801.short
Cytokine CCL5 and receptor CCR5 axis in glioblastoma multiforme
Miha Koprivnikar Kranjc, Metka Novak, Richard G. Pestell, Prof. Tamara T. Lah
The Journal of Association of Radiology and Oncology, Vol 53, Iss 4
https://www.degruyter.com/view/j/raon.2019.53...9-0057.xml
(3)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼